ClinicalTrials.Veeva

Menu

Women's Opioid Treatment Follow-up Study

Mass General Brigham logo

Mass General Brigham

Status

Completed

Conditions

Opioid Use Disorder

Treatments

Other: Treatment as usual
Behavioral: Gender-specific digital intervention (GSDI)

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT05776966
2023P000495
K23DA050780 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The goal of this study is to examine the feasibility of a gender-specific digital intervention for women with opioid use disorder. In this study, women with opioid use disorder will be randomized to receive treatment-as-usual plus a gender-specific digital intervention or treatment-as-usual only. Feasibility, satisfaction, and engagement with the intervention are the primary outcomes and will be measured post-intervention and at two-week, 6-week, and 12-week follow-up visits.

Full description

This study has two aims: (1) to demonstrate the feasibility of delivering a gender-specific digital intervention (GSDI) to women with opioid use disorder; (2) to collect preliminary estimates on the effect of the GSDI on engagement in medication treatment for opioid use disorder (MOUD). The investigators will conduct a pilot randomized controlled trial to achieve these aims. Women (N=40) who have recently initiated MOUD (within 30 days) will be enrolled and randomized to receive either the GSDI+TAU (gender-specific digital intervention + treatment as usual) or TAU-only. Feasibility, satisfaction, and engagement with the GSDI are the primary outcomes and will be measured post-intervention and at two-week, 6-week, and 12-week follow-ups. MOUD engagement will be assessed at two time-points: (1) 6-weeks and (2) 12-weeks post-enrollment to collect preliminary estimates on the effect of the GSDI on MOUD engagement.

Enrollment

39 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age 18 years of age or older
  • current opioid use disorder diagnosis
  • have a smartphone
  • initiated medication treatment for opioid use disorder in the past 30 days,
  • able to provide informed consent

Exclusion criteria

  • an acute psychiatric or medical condition, or cognitive impairment, that would impair the ability to complete study procedures
  • admitted to their current treatment episode on an involuntary status

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

39 participants in 2 patient groups

Gender-specific digital intervention plus treatment as usual (GSDI+TAU)
Experimental group
Description:
GSDI + TAU includes the addition of a gender-specific digital intervention (GSDI) to treatment as usual. The GSDI has a web-based component and a mobile component. The web-based portion of the GSDI includes: (1) gender-specific psychoeducation on substance use disorders, (2) specific education on opioid use disorder, including information about medication treatment for opioid use disorder, and (3) information on relapse-prevention skills. Participants complete the web-based portion immediately after completing baseline assessments. The mobile component includes three parts: (1) weekly self-report surveys of opioid and other substance use and medication adherence, (2) weekly skills-practice exercises, and (3) daily motivational messages encouraging self-care. Participants engage with the mobile component after completing the web-based portion until the end of the study (12 weeks).
Treatment:
Behavioral: Gender-specific digital intervention (GSDI)
Other: Treatment as usual
Treatment as usual (TAU)
Other group
Description:
TAU for opioid use disorder consists of a mix of medication treatment and individual and group therapy services across various levels of care: inpatient, residential, and outpatient. Residential treatment is for adults who have completed detoxification and require additional treatment in a structured environment. Inpatient treatment includes short-term care and detoxification treatment and incorporates a combination of group, family, and individual therapy targeted at medical stabilization, reducing the severity of the patient's symptoms, and providing resources and ongoing support to prevent relapse. Outpatient treatment is focused on comprehensive evaluation and stabilization.
Treatment:
Other: Treatment as usual

Trial contacts and locations

1

Loading...

Central trial contact

Dawn E. Sugarman, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems